Capricor Therapeutics, Inc. (CAPR) Options Chain - Yahoo Finance
This page provides options chain data for Capricor Therapeutics, Inc. (CAPR) from Yahoo Finance. It shows current stock prices, after-hours trading, and lists available call and put options for a specific expiration date, although no options are currently listed for this particular date. The data is delayed by 15 minutes.
CAPR Stock Jumps As Analysts Hike Price Targets Into FDA Date
Capricor Therapeutics (CAPR) stock surged over 12% following upgrades and increased price targets from B. Riley and Piper Sandler, driven by optimism ahead of a key FDA action date for deramiocel on November 22, 2026. Analysts highlight the attractive risk/reward profile and potential data release at the World Muscle Society conference. Despite current financial losses, the company's strong balance sheet and upcoming catalysts are attracting significant institutional and trading interest.
Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case
Capricor Therapeutics shares surged after presenting positive 24-month data from its Phase 3 HOPE-3 trial for deramiocel, a Duchenne muscular dystrophy drug. The data showed a significant slowing of upper-limb function decline, leading B. Riley to upgrade the stock to Buy with a raised price target. The results support an amended Biologics License Application, with the FDA extending its review period to November 22nd.
Capricor Therapeutics Stock Surges: What's Going On?
Capricor Therapeutics (NASDAQ: CAPR) stock surged after announcing positive 24-month results from its Phase 3 HOPE-3 trial for deramiocel in Duchenne Muscular Dystrophy (DMD), demonstrating a significant slowing of upper-limb function decline. This data supports the company's revised Biologics License Application (BLA) strategy, leading B. Riley to upgrade the stock from Neutral to Buy with a price target of $21. The surge marks a reversal from regulatory setbacks in July, as the company now focuses on preserving upper-limb function with an extended FDA PDUFA date of November 22.
CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call
Capricor Therapeutics Inc. (NASDAQ: CAPR) stock has surged by 17.98% following significant analyst upgrades and target hikes, driven by anticipation of the FDA's decision on its deramiocel therapy. B. Riley and Piper Sandler both issued "Buy" or "Overweight" ratings and substantially increased price targets, signaling strong confidence in a positive outcome for the November 22, 2026 FDA action date. This makes CAPR a high-volatility, catalyst-driven play for traders, supported by a healthy cash balance despite current unprofitability.
CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call
Capricor Therapeutics Inc. (CAPR) stock surged by 17.98% following significant analyst upgrades and price target hikes. B. Riley and Piper Sandler both raised their ratings and targets substantially, citing the upcoming FDA decision on deramiocel on November 22, 2026, as a major catalyst. The stock's volatility makes it a key focus for momentum and day traders, with strong cash reserves providing a financial runway despite current unprofitability.
CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call
Capricor Therapeutics (CAPR) stock rose by 14.24% following analyst upgrades and increased price targets due to positive sentiment surrounding its lead therapy, deramiocel, ahead of its November 22, 2026 FDA action date. B. Riley and Piper Sandler both upgraded the stock and significantly raised their price targets, indicating a bullish outlook on the company's regulatory path. While CAPR is an event-driven biotech with significant cash burn, its strong liquidity and the potential for deramiocel's approval are attracting institutional interest and driving volatility.
Capricor Therapeutics, Inc. stock Analysis: Bearish Trend and Intraday Pause
Capricor Therapeutics, Inc. stock closed at $8.57, down 1.61%, with a daily trend described as firmly bearish. While the daily chart indicates a clear bearish trend with the price below all major moving averages, the hourly chart suggests a pause in the sell-off, creating a divergence. The article highlights that the stock is at an inflection point due to conflicting signals from different timeframes and elevated volatility, with after-hours deramiocel HOPE-3 data and macro factors adding to the uncertainty.
Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ)
Capricor Therapeutics (CAPR) shares rose after new data on deramiocel, its experimental Duchenne muscular dystrophy treatment, became available from the World Muscle Society's 31st Annual Congress. The data, including 24-month HOPE-3 trial results, demonstrate longer-term benefits, showing deramiocel slowed deterioration in upper-limb function by 54% compared to placebo. These findings are significant for the ongoing FDA review and highlight the potential of Capricor's StealthX exosome technology in treating Duchenne and Pompe diseases.
Return on equity % of Capricor Therapeutics, Inc. – HAN:4LN2
This article provides financial information for Capricor Therapeutics, Inc. (HAN:4LN2) on TradingView, specifically focusing on its Return on Equity %. The page indicates that the market is currently closed, with no trades, and offers an overview of financials and other data.
Total equity of Capricor Therapeutics, Inc. – HAN:4LN2
This article provides financial information for Capricor Therapeutics, Inc. (HAN:4LN2) listed on the Hannover Stock Exchange. It specifically focuses on the company's total equity value over different periods, noting that the market is currently closed with no trades.
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Faruqi & Faruqi, LLP is reminding investors of the September 28, 2026 deadline to seek lead plaintiff status in a class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR). The lawsuit alleges that Capricor made misleading statements regarding its Duchenne muscular dystrophy therapy, Deramiocel, particularly concerning changes to its statistical analysis plan without FDA agreement, leading to significant stock drops. Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, may be eligible to participate.
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
Capricor Therapeutics, Inc. is facing a securities fraud class action lawsuit due to alleged misstatements regarding its lead product candidate, Deramiocel, and the integrity of its clinical data. The lawsuit claims Capricor failed to disclose changes to its statistical analysis plan for Deramiocel's Biologics License Application, leading to a significant stock drop after the FDA raised concerns. Investors who suffered losses have until September 28, 2026, to seek lead plaintiff status in the case.
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
The DJS Law Group has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged securities law violations. The lawsuit claims Capricor made false and misleading statements by modifying the statistical analysis plan for Deramiocel's clinical data without securing FDA agreement before resubmitting a Biologics License Application. Investors who purchased shares between December 17, 2025, and July 26, 2026, are encouraged to contact the DJS Law Group to discuss their rights and potential lead plaintiff appointments.
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged securities fraud. The lawsuit claims Capricor made misleading statements regarding its statistical analysis plan for Deramiocel's clinical data, leading investors to suffer losses when the truth emerged. Shareholders who purchased CAPR shares during the class period of December 17, 2025, to July 26, 2026, are encouraged to contact SBS before the September 28, 2026 deadline to discuss lead plaintiff opportunities.
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action
The Rosen Law Firm is reminding investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who purchased securities between December 17, 2025, and July 26, 2026, about the September 28, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Capricor made materially false and/or misleading statements regarding changes to its statistical analysis plan for Deramiocel's clinical data and the FDA's agreement to these changes, creating a substantial risk to regulatory approval. Investors are encouraged to join the class action to potentially recover damages.
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc.
Hagens Berman Sobol Shapiro LLP reminds investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about the upcoming September 28, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Capricor made misleading statements regarding clinical trial data and regulatory pathways for its lead product candidate, Deramiocel, particularly concerning undisclosed changes to its statistical analysis plan. This follows the FDA's extension of Capricor's Biologics License Application review and a significant stock drop after FDA briefing documents revealed issues with the HOPE-3 study's efficacy endpoints.
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky to Join Class Action Before September 28, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of investors who suffered losses due to alleged securities fraud between December 17, 2025, and July 29, 2026. The lawsuit claims that the company made false statements and concealed critical information regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, and the FDA's lack of agreement to these changes, posing a significant risk to regulatory approval. Investors are encouraged to contact Levi & Korsinsky to explore their rights and potentially join the class action.
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | FinancialContent
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made unauthorized changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop. Investors are urged to contact the firm before the September 28, 2026, deadline to potentially serve as a lead plaintiff.
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made unauthorized changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop on July 27, 2026. Investors are urged to contact Kaplan Fox before the lead plaintiff deadline of September 28, 2026.
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR) - Join by September 28, 2026 - Contact Levi & Korsinsky
A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) by Levi & Korsinsky, LLP. The lawsuit alleges that the company made false statements and concealed information regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, and the FDA's agreement to these changes, posing a significant risk to regulatory approval. Investors who purchased CAPR securities between December 17, 2025, and July 29, 2026, are encouraged to contact Levi & Korsinsky by September 28, 2026, to explore potential recovery.
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and its officers. The lawsuit alleges that Capricor made false and misleading statements regarding changes to its statistical analysis plan for Deramiocel and the FDA's stance on these changes, potentially impacting the drug's regulatory approval for Duchenne muscular dystrophy. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to join the lawsuit and may apply to be lead plaintiff by September 28, 2026.
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Capricor Therapeutics, Inc. (CAPR) Investors of September 28, 2026 Deadline
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of investors who suffered losses due to alleged securities fraud between December 17, 2025, and July 29, 2026. The lawsuit claims that the company made false statements and concealed critical information regarding changes to its statistical analysis plan for its lead product candidate, Deramiocel, without FDA agreement, leading to significant regulatory approval risk. Investors are reminded of the September 28, 2026 deadline to explore potential recovery under federal securities laws.
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) for allegedly making false and misleading statements to investors between December 17, 2025, and July 26, 2026. The lawsuit claims Capricor failed to disclose critical information regarding changes to its statistical analysis plan for Deramiocel's clinical data and the FDA's lack of agreement to these changes, posing a significant risk to regulatory approval. Investors who purchased Capricor securities during this period and suffered losses have until September 28, 2026, to apply to be appointed as lead plaintiff.
Securities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) - Levi & Korsinsky Reminds Investors of September 28, 2026
A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (CAPR) on behalf of investors who suffered losses due to alleged securities fraud between December 17, 2025, and July 29, 2026. The lawsuit claims that the company made false statements and concealed information regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, and the FDA's disagreement with these changes, which posed a significant risk to regulatory approval. Levi & Korsinsky, LLP is reminding investors of the September 28, 2026 deadline to explore potential recovery under federal securities laws.
SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR
SueWallSt is reminding investors of Capricor Therapeutics (NASDAQ: CAPR) about a pending class action lawsuit with a lead plaintiff deadline of September 28, 2026. The lawsuit alleges that Capricor made false or misleading statements between December 17, 2025, and July 26, 2026, leading to a significant stock drop after FDA briefing documents revealed unagreed changes to the HOPE-3 statistical analysis plan. Investors who purchased shares during this period and suffered losses may be eligible to recover their investments.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
Pomerantz LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding alleged securities fraud. The lawsuit stems from the FDA's Complete Response Letter for Capricor's Duchenne muscular dystrophy treatment, Deramiocel, citing a lack of substantial evidence of effectiveness and issues with the statistical analysis plan. Investors who purchased Capricor securities during the class period have until September 28, 2026, to apply for lead plaintiff status.
Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 28, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who suffered losses due to alleged securities fraud between December 17, 2025, and July 29, 2026. The lawsuit claims the company made false statements and concealed critical information regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, and the FDA's disagreement with these changes, posing a significant risk to regulatory approval. Investors are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery before September 28, 2026.
CAPRICOR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR
The Rosen Law Firm is encouraging investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to secure legal counsel before the September 28, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements regarding changes to the statistical analysis plan for Deramiocel and the FDA's agreement to these changes, leading to a significant risk in the regulatory approval process. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, may be entitled to compensation.
Capricor Therapeutics, Inc. (CAPR) Stock Price, News, Quote & History
This Yahoo Finance page provides a detailed overview of Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company focused on developing therapies for Duchenne muscular dystrophy and other diseases. It includes current stock performance, key financial metrics, analyst ratings, and company profile information, highlighting its lead product candidate Deramiocel in Phase 3 clinical trials. The article also touches on its exosome-based vaccine programs and historical stock performance against the S&P 500.
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor failed to disclose critical information regarding changes to its statistical analysis plan for its HOPE-3 study, which led to a significant stock price drop of 78.7% after FDA briefing documents revealed issues. Investors who suffered losses are encouraged to contact the firm to potentially serve as lead plaintiff by the September 28, 2026 deadline.
Kaplan Fox Continues to Alert Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Class Action Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a class action lawsuit deadline on September 28, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop after FDA briefing documents were released. Investors who suffered losses during the Class Period (December 17, 2025, and July 26, 2026) are encouraged to contact Kaplan Fox to learn about becoming a lead plaintiff.
Kaplan Fox Continues to Alert Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to a Class Action Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a class action lawsuit filed on behalf of those who purchased Capricor securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop. Investors have until September 28, 2026, to move the court to serve as a lead plaintiff.
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor's stock price fell significantly after the FDA released briefing documents indicating issues with the company's resubmitted Dermamiocel Biologics License Application. Investors who suffered losses are encouraged to contact Kaplan Fox before the September 28, 2026 deadline to serve as a lead plaintiff.
CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class Action over Clinical Data
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. and its executives for securities fraud. The lawsuit alleges Capricor made false statements regarding its lead product Deramiocel and the integrity of its clinical data, leading to significant stock drops. Investors have until September 28, 2026, to apply to be a lead plaintiff in the case.
Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis plan for Deramiocel and the FDA's agreement to these changes, posing a significant risk to regulatory approval. Investors with losses are urged to contact the firm before the September 28, 2026 deadline to discuss their legal options and apply to be lead plaintiff.
1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announced that investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who purchased securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status in a class action lawsuit. The lawsuit alleges that Capricor made misleading statements and failed to disclose critical changes to the statistical analysis plan for its lead product candidate, Deramiocel, without FDA agreement, leading to significant stock drops after FDA briefing documents revealed these issues and an advisory committee voted against the drug's efficacy.
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
Hagens Berman Sobol Shapiro LLP has notified investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of an upcoming September 28, 2026, lead plaintiff deadline for a securities class action lawsuit. This follows the FDA's extension of the review period for Capricor's Biologics License Application (BLA) for deramiocel, a treatment for Duchenne muscular dystrophy. The lawsuit alleges that Capricor made misleading statements about clinical trial data and statistical analysis plan (SAP) changes, leading to a significant stock price collapse after the FDA revealed unagreed-upon modifications.
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc.
Hagens Berman Sobol Shapiro LLP has announced a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), urging investors with substantial losses to come forward by the September 28, 2026 deadline. The lawsuit stems from alleged materially false and misleading statements made by Capricor regarding clinical trial data and statistical analysis plan changes for its lead product candidate, Deramiocel, leading to a significant stock price crash after the FDA revealed unagreed-upon modifications to the trial data. This follows the FDA's extension of the review period for Capricor's Biologics License Application for Deramiocel.
Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
Robbins LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor misled investors about the FDA approval prospects for its lead product candidate, Deramiocel, by failing to disclose changes to its statistical analysis plan. Investors who suffered significant losses during this period are encouraged to contact Robbins LLP before the September 28, 2026, lead plaintiff deadline.
Faruqi & Faruqi, LLP Urges Capricor Therapeutics, Inc. (CAPR) Investors to Seek Counsel Before the September 28, 2026 Lead Plaintiff Deadline in the Securities Class Action
Faruqi & Faruqi, LLP is urging investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to seek counsel before the September 28, 2026 lead plaintiff deadline in a federal securities class action lawsuit. The lawsuit alleges that Capricor and its executives made misleading statements and failed to disclose critical information regarding changes to the statistical analysis plan for Deramiocel's clinical data and the FDA's lack of agreement, which significantly risked regulatory approval. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to contact the firm to discuss their options, as Capricor shares reportedly fell 64% after corrective disclosures.
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
Capricor Therapeutics announced that data from its HOPE-3 trial and its open-label extension for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD), will be presented at the 31st Annual Congress of the World Muscle Society in September 2026. The presentations will include 24-month skeletal muscle and cardiac outcomes, supporting the recent major amendment to Deramiocel's Biologics License Application (BLA). The company also plans to present preclinical data from its StealthX™ exosome platform.
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
Berger Montague PC has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit stems from a significant stock drop after the FDA raised concerns about Capricor's Deramiocel BLA due to changes in its statistical analysis plan, questioning its scientific justification and effectiveness. Investors have until September 28, 2026, to seek lead plaintiff status.
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) for alleged violations of federal securities laws. The lawsuit claims that Capricor made false and misleading statements regarding changes to its statistical analysis plan for Deramiocel clinical data, which the FDA had not agreed to, thus risking regulatory approval. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to join the lawsuit and have until September 28, 2026, to request to be appointed as lead plaintiff.
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 28, 2026 Deadline - RGRD Law
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for Deramiocel, its lead product candidate for Duchenne muscular dystrophy, and that the FDA had not agreed to these changes. Investors have until September 28, 2026, to seek appointment as lead plaintiff in the case.
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT
Bernstein Liebhard LLP has issued a shareholder alert for Capricor Therapeutics, Inc. (CAPR), reminding investors of the upcoming September 28, 2026 deadline to join a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements regarding its business operations and financial stability between December 17, 2025, and July 6, 2026, leading to inflated stock prices and investor losses. Shareholders who purchased shares during this period and suffered losses are encouraged to contact the firm.
Capricor Therapeutics shares rise 2.5% following August FDA update
Capricor Therapeutics (NASDAQ:CAPR) shares rose 2.5% in pre-market trading, following a positive August FDA update regarding its biologics license application for deramiocel. This rise occurred despite a broader market decline, and follows Cantor Fitzgerald upgrading the stock to "Overweight" with a significantly increased price target of $28. The company also reported a strong cash position sufficient to fund operations for over 12 months as it awaits a November PDUFA decision.
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor's stock price fell significantly after the FDA released briefing documents questioning changes to the statistical analysis plan for their Dermamiocel Biologics License Application. Investors are encouraged to contact Kaplan Fox before the September 28, 2026 deadline to learn more about serving as a lead plaintiff.
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made unauthorized changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop on July 27, 2026. Investors have until September 28, 2026, to move the court to serve as a lead plaintiff.
Capricor Therapeutics, Inc. (CAPR) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 28, 2026 Lead Plaintiff Deadline
Hagens Berman has filed a securities fraud class action lawsuit against Capricor Therapeutics (CAPR), with a lead plaintiff deadline of September 28, 2026. The lawsuit alleges that Capricor made misleading statements regarding clinical trial data for its lead product candidate, Deramiocel, and failed to disclose changes to its statistical analysis plan without FDA agreement. These allegations came to light after an FDA briefing document revealed unagreed-upon post-hoc modifications, causing a significant stock price drop.
